TRAIL (TNFSF10)
(Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))
Type de proteíne
Recombinant
Attributs du protein
Trimer
Origine
Humain
Source
HEK-293 Cells
Purification/Conjugué
Cette TRAIL protéine est marqué à la His-DYKDDDDK Tag.
Séquence
Gly118-Gly281
Pureté
> 95% as determined by Tris-Bis PAGE,> 95% as determined by HPLC
Stérilité
0.22 μm filtered
niveau d'endotoxine
Less than 1EU per μg by the LAL method.
Biological Activity Comment
Immobilized TRAIL Trimer, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Human TRAIL R1, hFc Tag with the EC50 of 49.2ng/ml determined by ELISA. See testing image for detail.
TNFSF10
Origine: Humain
Hôte: Escherichia coli (E. coli)
Recombinant
> 95 % as determined by reducing SDS-PAGE.
Func
Active
Restrictions
For Research Use only
Format
Liquid
Buffer
Supplied as 0.22μm filtered solution in PBS ( pH 7.4).
Stock
-80 °C
Stockage commentaire
Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please do not repeated freeze-thaw cycles.
Date de péremption
12 months
Antigène
TRAIL (TNFSF10)
(Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))
Apo-2L, TRAIL, CD253, TNFSF10, Apo-2 ligand, APO2L, TL2,Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that can initiate the apoptosis pathway by binding to its associated death receptors DR4 and DR5. The activation of the TRAIL pathway in inducing tumor-selective apoptosis leads to the development of TRAIL-based cancer therapies, which include recombinant forms of TRAIL, TRAIL receptor agonists, and other therapeutic agents.
Poids moléculaire
60 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Tris-Bis PAGE result.